Presentation is loading. Please wait.

Presentation is loading. Please wait.

FDA H5N1 Update: Classification of H5N1 Viruses and Development of Vaccine Reference Strains FDA H5N1 Update: Classification of H5N1 Viruses and Development.

Published byMoris Hawkins Modified over 9 years ago

Similar presentations

Presentation on theme: "FDA H5N1 Update: Classification of H5N1 Viruses and Development of Vaccine Reference Strains FDA H5N1 Update: Classification of H5N1 Viruses and Development."— Presentation transcript:

1 FDA H5N1 Update: Classification of H5N1 Viruses and Development of Vaccine Reference Strains FDA H5N1 Update: Classification of H5N1 Viruses and Development of Vaccine Reference Strains Nancy J. Cox, Ph.D. Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza Centers for Disease Control and Prevention

2 History of H5N1  Currently 2 discrete lineages of H5 HAs descended from the A/Gs/Guangdong/96 have infected humans  1997 poultry outbreak in Hong Kong 18 human cases, 6 deaths 18 human cases, 6 deaths Direct avian to human transmission: limited H-2-H transmission Direct avian to human transmission: limited H-2-H transmission  2003 ongoing poultry outbreaks and spread 2 human cases, 1 death in Hong Kong 2 human cases, 1 death in Hong Kong 1 death in Beijing (from time of SARS) 1 death in Beijing (from time of SARS)  End of 2003 - Today 258 human cases, 154 deaths 258 human cases, 154 deaths Azerbaijan, Cambodia, China, Djbouti, Egypt, Indonesia, Iraq, Laos, Nigeria, Thailand, Turkey, Vietnam Azerbaijan, Cambodia, China, Djbouti, Egypt, Indonesia, Iraq, Laos, Nigeria, Thailand, Turkey, Vietnam

3 Vietnam Cases: 93 Deaths: 42 Thailand Cases: 25 Deaths: 17 Cambodia Cases: 6 Deaths: 6 Indonesia Cases: 81 Deaths: 63 China Cases: 22 Deaths: 14 Turkey Cases: 12 Deaths: 4 Iraq Cases: 3 Deaths: 2 Azerbaijan Cases: 8 Deaths: 5 Egypt Cases: 22 Deaths: 13 Influenza A (H5N1) in Humans, 2003-07 * * December 2003 – February 2007 275 cases and 167 deaths Djibouti Cases: 1 Deaths: 0

4 WHO H5N1 Vaccine Development: Principles and Practices  Development of H5N1 vaccines is one component of WHO’s overall strategy for pandemic preparedness  WHO’s 4 Collaborating Centers for Influenza Reference and Research along with 4 additional H5 Reference Laboratories share H5N1 antigenic and genetic data frequently  WHO convenes periodic teleconferences of H5 Reference Laboratory representatives to discuss data and apportion tasks required for vaccine candidate reference virus production  Development of appropriate H5N1 vaccines requires integration of antigenic, genetic and epidemiologic data from human and veterinary health sectors  H5N1 vaccine candidate reference viruses are chosen on the basis of antigenic and genetic properties and epidemiologic information

5 Circulation of H5N1 Viruses  HA sequences of the majority of H5N1 viruses in avian species segregate into 2 distinct phylogenetic clades  Clade 1 viruses circulated in Cambodia, Thailand and Viet Nam and caused human infections during 2004 and 2005 -and in Thailand in 2006  Clade 2 viruses circulated in birds in China and Indonesia during 2003–2004 and spread westward during 2005 and 2006 to the Middle East, Europe and Africa  Clade 2 viruses have caused the majority of human Infections since late 2005  Multiple sub-clades of clade 2 have been distinguished, three of which (subclades 2.1, 2.2 and 2.3) have been responsible for human cases and differ in geographical distribution

6 H5N1 Current Status (Late 2005 to the Present)  The majority of H5N1 viruses detected in avian species in Africa, Asia and Europe and associated with sporadic human infections are in Clade 2  Clade 2.1 viruses circulated in poultry and caused human infections in Indonesia; clade 2.2 viruses caused outbreaks in birds in Africa, Asia and Europe and were most recently associated with human infections in Egypt and Nigeria; viruses in clade 2.3 caused poultry outbreaks and human cases in China  Viruses outside this classification nomenclature were isolated from domestic poultry in Asia – two emerging clades are represented by A/goose/Guiyang/337/06 and A/chicken/Shanxi/2/2006 viruses

7 Hong Kong/156/97 Vietnam/JP14/05 ck/Cambodia/013LC1b/05 Vietnam/1194/04 Vietnam/1203/04 Vietnam/HN30408/05 Thailand/16/04 Vietnam/JPHN30321/05 Clade 1 Hong Kong/213/03 Indonesia/CDC523/06 Indonesia/CDC699/06 Indonesia/CDC326/06 Indonesia/5/05 Indonesia/CDC184/05 Indonesia/7/05 dk/KulonProgoBBVET9/04 ck/Indonesia/CDC25/05 Indonesia/6/05 ck/Brebes/BBVET2/05 Indonesia/CDC594/06* ck/Dairi/BPPVI/05 Clade 2 Subclade 1 ck/Yunnan/374/04 ck/Yunnan/115/04 ck/Yunnan/493/05 ck/Yunnan/447/05 dk/Guangxi/13/04 ck/Guangxi/12/04 whooping swan/Mongolia/244/05 bar headed gs/Qinghai/1A/05 * Turkey/65596/06 Turkey/15/06 Iraq/207NAMRU3/06 ck/Nigeria/641/06 mld/Italy/332/06 turkey/Turkey/1/05 Egypt/2782NAMRU3/06 Djibouti/5691NAMRU3/06 ck/Nigeria42/06 migratory dk/Jiangxi/2136/05 gs/Kazakhstan/464/05 ck/Krasnodar/01/06 Azerbaijan/011162/06 swan/Iran/754/06 Clade 2 Subclade 2 dk/Laos3295/06 Anhui/1/05 Anhui/2/05 Japanese white-eye/Hong Kong/1038/06 ck/Malaysia935/06 Vietnam/30850/05 Guangxi/1/05 dk/Hunan/15/04 qa/Guangxi/575/05 dk/Vietnam/Ncvdcdc95/05 Clade 2 Subclade 3 migratory dk/Jiangxi/1653/05 gs/Guangdong/1/96 * Karo cluster Indonesia/CDC625/06* H5 HA

8 HI Reactions of Influenza H5 Viruses 1 A/VIETNAM/1194/04 2 A/VIETNAM/1203/04 3 A/THAILAND/16/04 4 A/INDONESIA/5/05 RG 5 A/INDONESIA/CDC357/06 6 A/INDONESIA/CDC625/06* 7 A/TURKEY/15/05 8 A/w.swan/MG/244/05 RG 9 A/b-h gs/QINGHAI/1/05 RG 10 A/turkey/TURKEY/1/05 11 A/duck/HUNAN/15/04 12 A/ANHUI/1/05 13 A/GUANGXI/1/05 640 320 nd 80 nd 80 nd 160 <10 40 20 10 nd 80 40 10 nd 160 <10 20 10 <10 10 <10 nd 80 20 10 320 80 40 80 20 <10 20 nd <10 320 640 40 80 nd 20 <10 10 nd 80 40 160 80 1280 640 320 nd 20 10 nd <10 40 640 320 80 nd <10 10 <10 20 <10 20 40 640 320 1260 160 <10 10 <10 20 40 80 160 1280 640 320 160 20 40 <20 nd 40 nd 320 160 320 nd 160 80 40 20 40 20 40 nd 160 nd 10 <10 40 20 40 10 20 nd 160 640 320 nd 20 10 20 10 20 40 10 20 nd 160 A/VN/1194/04A/VN/1203/04 A/TH/16/04 A/INDO/5/05A/INDO/357/06A/INDO/625/06 A/TURKEY/15/05A/ws/MG/244/05A/bhg/QINGHAI/1/05 A/ty/TURKEY/1/05A/dk/HUNAN/15/04 A/ANHUI/1/05 A/GUANGXI/1/05 Reference Ferret Antisera Clade 2-1 Clade 2-2 Clade 2-3 Clade 1

9 HI Reactions of Influenza H5 Viruses Reference Ferret Antisera 1 A/VIETNAM/1203/04 * 2 A/THAILAND/16/04 3A/INDONESIA/5/05 * 4A/INDONESIA/357/06 5A/w.swan/MG/244/05 6 A/b-h gs/QINGHAI/1/05 7A/ANHUI/1/05 * 8A/GUANGXI/1/05 160 <10 40 20 10 40 10 VN120304 160 <10 20 10 <10 20 TH1604 <10 320 10 40 20 INDO505 <10 320 640 80 10 INDO35706 <10 20 40 320 1260 10 <10 wsMG24405 40 80 640 320 40 QINGHAI05 10 <10 40 20 10 20 640 320 ANHUI05 20 10 20 10 20 160 GUANGXI05 HK/156/97 Vietnam/1194/04 Vietnam/1203/04 1 HK/213/03 Indonesia/5/05 2-1 w. swan/Mongolia/244/05 b.h.gs/Qinghai/1A/05 ty/Turkey/1/05 2-2 Anhui/1/05 2-3 gs/Guangdong/1/96

10 Hong Kong/156/97 Vietnam/1194/04 Vietnam/1203/04 Clade 1 Hong Kong/213/03 Indonesia/5/05 Clade 2-3 whooping swan/Mongolia/244/05 bar headed gs/Qinghai/1A/05 * turkey/Turkey/1/05 Anhui/1/05 gs/Guangdong/1/96 Resistant Asn-31 Sensitive Ser-31 Clade 2-1 ~80% resistant Asn-31 or Ala-27 Clade 2-2 Sensitive Ser-31 H5N1 Virus Resistance to M2 Channel Blockers

11 Hong Kong/156/97 Vietnam/1194/04 Vietnam/1203/04 Clade 1 Hong Kong/213/03 Indonesia/5/05 Clade 2-3 whooping swan/Mongolia/244/05 bar headed gs/Qinghai/1A/05 * turkey/Turkey/1/05 Anhui/1/05 gs/Guangdong/1/96 Sensitive Several resistant mutants isolated from treated patients Sensitive Clade 2-1 Sensitive Clade 2-2 Generally Sensitive - but moderately resistant viruses detected H5N1 Resistance to Neuraminidase Inhibitors

12 HI REACTIONS OF INFLUENZA H5 VIRUSES

13 ? ck/Shannxi/62/04 ck/Yunnan/447/05|ck/Yunnan/493/05 dk/Guangxi/13/04 ck/Yunnan/30/04 ck/Yunnan/115/04 ck/Yunnan/374/04 Indonesia/7/05 Indonesia/5/05 Indonesia/CDC742/06 Indonesia/CDC940/06 Indonesia/CDC1031/07 Indonesia/CDC1047/07 Indonesia/CDC887/06 Indonesia/CDC938/06 Indonesia/CDC1032/07 Indonesia/CDC1046/07 Barhdgs/Qinghai/1A/05 ck/Liaoning/23/05 Barhdgs/Qinghai/12/05 ck/Krasnodar/01/06 Azerbaijan/001161/06 swan/Iran/754/06 Turkey/15/06 Iraq/207NAMRU-3/06 ck/Nigeria/641/06 whswan/Mongolia/244/05 tky/Turkey/1/05 Egypt/14724NAMRU-3/06 Djibouti/5691NAMRU-3/06 dk/Egypt/22533/06 Egypt/0636NAMRU-3/07 egret/Egypt/1162NAMRU-3/06 dk/Hunan/15/04 scalybreastedMunia/HongKong/45/07 JapaneseWhiteEye/HongKong/1038/06 Anhui/1/05 dk/Laos/3295/06 ck/Malaysia/935/06 common magpie/Hong Kong/645/06 Guangxi/1/05 House Crow/Hong Kong/719/07 JapaneseWhiteEye/Hong Kong/737/07 WhiteBackedMunia/HongKong/828/07 Thailand/676/05 Vietnam/JP14/05 ck/Cambodia/013LC1b/05 Vietnam/JPHN30321/05 Vietnam/1203/04 Vietnam/1194/04 Vietnam/HN30408/05 Thailand/16/04 Hong Kong/213/03 migdk/Jiangxi/1653/05 ck/Hunan/41/04 ck/Hunan/2292/06 ck/Shanxi/2/06 ck/Myanmar/06010011B/06 ck/Yunnan/71/05 ck/Guiyang/237/06 gs/Guiyang/1325/06 dk/Guiyang/50406 gs/Fujian/bb/03 gs/Vietnam/GZ-3/05 Hong Kong/156/97 gs/Guangdong/1/96 Candidate Vaccine Reference Viruses Clade 2.1 Clade 2.2 Clade 2.3 Clade 1 Evolution of the H5N1 Hemagglutinin Gene New subgroup

14 Conclusions  H5N1 viruses remain a pandemic threat but have not yet developed to the ability to be transmitted efficiently from person-to-person  It is not able to predict which if any of the H5N1 antigenic/genetic variants might acquire the ability to be transmitted efficiently  Distinct geographical distribution of H5N1 genetic and antigenic variants have been identified  In this instance, specific WHO pre-pandemic vaccine recommendations are not appropriate because it is not possible to predict which of the viruses in the distinct antigenic/genetic groups might acquire the ability to become efficiently transmissible

15 Availability of Vaccine Viruses and Reagents  rg A/Viet Nam/1203/2004 (Clade 1) – available from St. Jude CRH Antigen and sheep serum available from CBER Antigen and sheep serum available from CBER  rg A/Viet Nam/1194/2004 (Clade 1) – available from NIBSC Antigen and sheep serum available from NIBSC Antigen and sheep serum available from NIBSC  rg A/Indonesia/05/2005 (Clade 2.1) – available from CDC Antigen and sheep serum - available soon from CBER Antigen and sheep serum - available soon from CBER  rg A/Turkey/turkey/1/2005 (Clade 2.2) – available from NIBSC Antigen and sheep serum available from NIBSC Antigen and sheep serum available from NIBSC  rg A/BHG/Qinghai Lake/1A/05 (Clade 2.2) – available from St. Jude Reagents not yet in production Reagents not yet in production  rg A/whooper swan/Mongolia/244/2005 (Clade 2.2) – available for research Reagents not in production Reagents not in production  rg A/Anhui/1/05 (Clade 2.3) – available from CDC Reagents not yet in production Reagents not yet in production

16 Acknowledgements  WHO National Influenza Centers  WHO Collaborating Centers and Regulatory Authorities in London, Tokyo, Melbourne, Canberra, and Memphis  WHO H5 Reference Laboratories  WHO Regional Offices  WHO Headquarters in Geneva  Many colleagues in Azerbaijan, Cambodia, China, Djibouti, Egypt, Indonesia, Iraq, Nigeria, Thailand, Turkey, Vietnam and other affected countries  Ministries of Agriculture in affected countries and FAO and OIE members  Members of the Influenza Division, CDC

17 Thank You

Download ppt "FDA H5N1 Update: Classification of H5N1 Viruses and Development of Vaccine Reference Strains FDA H5N1 Update: Classification of H5N1 Viruses and Development."

Similar presentations

Will the Avian Flu Become the Next Epidemic?

Will the Avian Flu Become the Next Epidemic?
Research Issues in Animal Surveillance and Pandemic Planning Robert G. Webster, PhD Division of Virology Department of Infectious Diseases St. Jude Children’s.

Research Issues in Animal Surveillance and Pandemic Planning Robert G. Webster, PhD Division of Virology Department of Infectious Diseases St. Jude Children’s.
Highly Pathogenic Avian Influenza IN EGYPT Presentation by Prof. Dr. Hamed Samaha CVO, GOVS HPAI Technical Meeting Rome, 27-29 June.

Highly Pathogenic Avian Influenza IN EGYPT Presentation by Prof. Dr. Hamed Samaha CVO, GOVS HPAI Technical Meeting Rome, June.
U.S. Pandemic Influenza Preparedness and Response: Planning and Activities “The pandemic influenza clock is ticking. We just don’t know what time it is.”

U.S. Pandemic Influenza Preparedness and Response: Planning and Activities “The pandemic influenza clock is ticking. We just don’t know what time it is.”
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Avian Influenza A(H5N1) and Risks to Human Health Technical Meeting on Highly Pathogenic Avian Influenza and Human H5N1 infection Rome 27 - 29 June 2007.

Avian Influenza A(H5N1) and Risks to Human Health Technical Meeting on Highly Pathogenic Avian Influenza and Human H5N1 infection Rome June 2007.
Avian Influenza – The Bird Flu

Avian Influenza – The Bird Flu
Avian Flu Yurij Kobasa & Ambrish Patel. Overview 1. Background Information 2. Brief overview of genome structure 3. Origin/History 4. Geographical Distribution.

Avian Flu Yurij Kobasa & Ambrish Patel. Overview 1. Background Information 2. Brief overview of genome structure 3. Origin/History 4. Geographical Distribution.
Protecting American Agriculture 1 Avian Influenza: Agricultural Perspectives & Interventions December 14, 2005.

Protecting American Agriculture 1 Avian Influenza: Agricultural Perspectives & Interventions December 14, 2005.
So Far Primarily an Avian Disease Considering geographic spread and lethality in birds – very little human disease Fear that the virus may develop the.

So Far Primarily an Avian Disease Considering geographic spread and lethality in birds – very little human disease Fear that the virus may develop the.
Control of the H5N1 influenza epidemic at the source Patrick Woo.

Control of the H5N1 influenza epidemic at the source Patrick Woo.
Mmmmm Mohamed M. B. Alnoor CHP400 COMMUNITY HEALTH PROGRAM-II Avian Influenza H5N1 Epidemiology & Control mmmmm.

Mmmmm Mohamed M. B. Alnoor CHP400 COMMUNITY HEALTH PROGRAM-II Avian Influenza H5N1 Epidemiology & Control mmmmm.
Nicole J. Cohen, MD, MSc Chicago Department of Public Health

Nicole J. Cohen, MD, MSc Chicago Department of Public Health
Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.

Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.
By Andrew Garaniel University of California, Irvine

By Andrew Garaniel University of California, Irvine
AVIANAVIAN FLUFLU Ginny Codd Viruses: Infection and Ecology.

AVIANAVIAN FLUFLU Ginny Codd Viruses: Infection and Ecology.
ONE WORLD. ONE HEALTH Rockefeller University New York – 29 September 2004 History of zoonotic avian influenza By F.X. Meslin Co-ordinator, Strategy development.

ONE WORLD. ONE HEALTH Rockefeller University New York – 29 September 2004 "History of zoonotic avian influenza" By F.X. Meslin Co-ordinator, Strategy development.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
Preparing for an Influenza Pandemic in Westminster Health and Community Services Overview and Scrutiny Committee 9 Oct 2006 Dr Margaret Guy Director of.

Preparing for an Influenza Pandemic in Westminster Health and Community Services Overview and Scrutiny Committee 9 Oct 2006 Dr Margaret Guy Director of.
Influenza Virus Vaccine 2011-2012 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Similar presentations

Ads by Google